• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    O

    Ochsner Health System

    EST. 1942
    1,808论文总数
    3.8万引用总数

    Ochsner Health System is a not-for-profit health system based in the New Orleans metropolitan area of southeast Louisiana, United States. As of 2021[update] it is the largest non-profit, academic healthcare system operating in Louisiana, with 40 medical facilities across the state. Its flagship hospital, Ochsner Medical Center, has been ranked the number one hospital in Louisiana for the past decade. It also has other clinics and medical centers in Greater New Orleans, Baton Rouge, Shreveport, Monroe, Lafayette, and other locations across Louisiana and Mississippi.

    论文量&引用量时间轴

    机构学者

    论文(1808)

    年份
    起
    –
    止
    排序
    1Cardiac Resynchronisation Therapy among Adults with a Systemic Right Ventricle: a Multicentre Experience
    Flavia Fusco,Giancarlo Scognamiglio,Mikael Dellborg,Payam Dehghani, Susan M Jameson,W Aaron Kay,Jonathan W Cramer, Isabelle Vonder Muhll,Eric V Krieger,Fred H Rodriguez, Luke J Burchill,Jeremy Nicolarsen,

    BACKGROUND:Cardiac resynchronisation therapy (CRT) is a key treatment for heart failure (HF) in acquired heart disease, but its benefits in adults with congenital heart disease and a systemic right ventricle (sRV) remain unclear. This study aimed to assess whether CRT improves outcomes in patients with sRV. METHODS:This is an international, retrospective study including patients >18 years from 33 centres with transposition of the great arteries (TGA) following atrial switch operation and congenitally corrected TGA. The primary endpoint included overall survival and survival free from HF. The secondary endpoint was a composite of death, hospitalisation for HF, heart transplant, mechanical support and ventricular tachycardia/implantable cardioverter-defibrillator therapies. RESULTS:We identified 105 out of 1721 patients (3.5%) who underwent CRT. Median follow-up after CRT implant was 4.6 (1.6-8) years. QRS improvement was limited to those with previous pacing (167±35 vs 154±28 ms; p=0.002). Following CRT, there was no significant change in B-type natriuretic peptide values, peak VO2 and tricuspid regurgitation severity by echocardiography. CRT complications occurred in 10 (9.5%), though they were usually minor. Patients with CRT were propensity-matched to controls according to age, sex, anatomy, presence of complex disease, previous HF and sRV dysfunction at baseline. At univariable analysis, CRT (HR 4.39-95%, CI 1.6 to 11.9; p=0.003), older age and moderate-to-severe sRV dysfunction at baseline were predictive of death, while CRT (HR 3-95%, CI 1.3 to 7; p=0.01) and sRV dysfunction were associated with HF admission. By multivariable analysis, CRT (HR 8.8-95%, CI 2.9 to 26.6; p=0.0001) and age (HR 1.1%-95%, CI 1.01 to 1.15; p<0.0001) were independently associated with poorer outcome. CONCLUSION:In this retrospective study in the largest population thus far described with an sRV, CRT implant was not associated with improved survival, even after controlling for key confounders.

    2026Heart (British Cardiac Society)(2026)引用:7
    引用
    AI阅读
    加入学术空间
    2Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline.
    Christina M Lockwood, Hans J Messersmith,Annette S Kim,Padma Sheila Rajagopal,Umang Swami,Rena Xian,Dara Aisner,Maria E Arcila, Florence Kurttila,Christine M Lovly,Jason D Merker,Kanika G Nair,

    ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more. PURPOSE:To provide guidance on the use of circulating tumor DNA (ctDNA) testing in patients with solid tumors or lymphoma. METHODS:A systematic review by a multidisciplinary panel with patient representation was conducted. The PubMed database was searched from January 2017 to February 2025. Guideline recommendations were based on consideration of the identified evidence. RESULTS:Fifty-four meta-analyses and 22 study reports were identified, including reports of seven randomized trials. RECOMMENDATIONS:ctDNA testing for tumor genetic alterations may be used in situations where: tumor tissue testing is challenging, not feasible, or tumor biopsy represents unacceptable risks to the patient; tumor tissue testing results may not be available within a clinically actionable time frame to determine appropriate management options; or a drug's regulatory approved indication allows for or requires ctDNA testing. If ctDNA testing results are negative, inconclusive, or inconsistent with the clinical scenario, tissue-based confirmation should be sought. Other than testing for genetic alterations, ctDNA testing may be offered if a specific, evidence-based action can be taken with the results or there is conflict or ambiguity with standard-of-care assessment that may be resolved by ctDNA testing. Fractional, percentage, or concentration-based measures of ctDNA or total cell-free DNA concentration are not recommended as a surrogate measure of disease. The panel recognizes this is a rapidly evolving field and guidelines are anticipated to change, bringing in tumor-type specific recommendations and incorporating more data on molecular residual disease settings.Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines.

    2026JCO oncology practice(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Recommendations from the Blue Ribbon Panel on Fluoroscopy Safety
    Dustin A Gress, M Mahesh, Kevin W Dickey, John F Angle,D Duane Baldwin,Stephen Balter, Wayne Batchelor, Lisa Bruedigan, Christopher Davis, Deirdre Elder, R Paul Guillerman,Maged N Guirguis,

    There are many challenges associated with the safe use of fluoroscopy. These challenges include but are not limited to highly variable regulatory requirements, scope of practice concerns, inconsistent education and training, and lack of staff empowerment. Challenges are further compounded by the increasing use of fluoroscopy across a wide range of medical specialties. To facilitate consensus on how to address the issues, the ACR convened the multidisciplinary Blue Ribbon Panel on Fluoroscopy Safety (BRP-FS), with 32 organizations represented. The goal of the BRP-FS is to establish multi- and interspecialty consensus standards for the safe use of fluoroscopy in health care, including minimum and uniform standards for the education and training of fluoroscopy users that apply across geographic and professional boundaries, for the benefit of all patients and health care providers. Recommendations are made for local practices, professional organizations, industry, regulatory agencies, and accreditation bodies. Foundational to the recommendations of the BRP-FS are the personnel training and procedure classification frameworks in National Council on Radiation Protection and Measurement Commentary No. 33.

    2026Journal of the American College of Radiology JACR(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma.
    Zachary T Berman,Cynthia De la Garza-Ramos, S Ali Montazeri, Christopher D Malone,Tyler Sandow, Juan Gimenez,Shamar Young,Nicholas Fidelman, Kurt T Pianka,Alex Sher, Tharun Alamuri, Shin Mei Chan,

    Background Complete pathologic necrosis (CPN) at liver transplant is a positive predictor of freedom from recurrence and overall survival for patients with hepatocellular carcinoma (HCC). Comprehensive authorized user parameters for yttrium 90 radiation segmentectomy CPN rates at explant remain undefined. Purpose To evaluate established outcomes for radiation segmentectomy before liver transplant and determine optimal parameters to achieve CPN among patients with treatment-naive HCC. Materials and Methods This multicenter retrospective study included patients with treatment-naive HCC who underwent glass microsphere radiation segmentectomy before liver transplant from January 2016 to December 2024. Treatment parameters were compared for patients that achieved CPN versus those without CPN using Mann-Whitney U or χ2 tests. Receiver operating characteristic analysis was performed to determine treatment parameter thresholds and subsequently predict CPN. Results A total of 303 patients with 364 tumors were included in the study. Tumors had a median size of 2.4 cm (IQR, 2.0-3.1 cm) and demonstrated a CPN rate of 68% (246 of 364). Compared with tumors without CPN, those with CPN had a higher microsphere activity (median, 1242 Bq vs 1203 Bq; P < .03), microspheres per milliliter (median, 9000 per mL vs 7600 per mL; P = .02), single-compartment dose (median, 544 Gy vs 379 Gy; P < .001), and angiosome-to-tumor volume ratio (median, 25.2 vs 15.6; P = .02). Multivariable logistic regression showed that a microsphere activity of 1087 Bq or greater (P = .03), a dose of 440 Gy or greater (P < .001), and an angiosome-to-tumor volume ratio of 16 or greater (P < .001) were independent predictors of CPN. There was a positive association between the number of optimized parameters and CPN at liver transplant, with a positive predictive value of 74% (198 of 269) with one threshold met and 91% (57 of 63) with all thresholds met (P < .001). Conclusion Among patients with treatment-naive HCC, glass microsphere radiation segmentectomy before liver transplant achieved high rates of CPN, which was associated with optimized parameter thresholds determined for microsphere activity, microspheres per milliliter, dose, and angiosome-to-tumor volume ratio. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Gordon and Lewandowski in this issue.

    2026Radiology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Cognitive Function in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
    Rebekka Rust,Susanna Asseyer,Patrick Schindler,Claudia Chien, Sophia Rekers,Carsten Finke,Frederike Cosima Oertel,Klemens Ruprecht,Sven Jarius,Brigitte Wildemann, Velina Chavarro, Tanja Schmitz-Hübsch,

    BACKGROUND:Data on cognition in adult patients with myelin oligodendrocyte glycoprotein antibody-associated disease (pwMOGAD) are scarce. OBJECTIVE:To examine cognitive function in pwMOGAD and assess relative risks (RR) for cognitive impairment (CImp) in pwMOGAD relative to healthy controls (HC), aquaporin 4-immunoglobulin G positive neuromyelitis optica spectrum disorders (pwAQP4+NMOSD), and double-seronegative NMOSD (pwdsNMOSD) compared to HC. METHODS:Data derived from a cohort with neuroimmunological disorders. Cognitive performance was assessed using Rao's brief repeatable battery of neuropsychological tests, compared to HC using confounder-adjusted linear regressions. CImp was defined as performing two standard deviations below the HC mean in any subtest. RR for CImp was calculated using generalized linear models. RESULTS:We evaluated cognitive performance of 21 pwMOGAD and 25 HC. CImp was additionally determined in 43 pwAQP4+NMOSD and 15 pwdsNMOSD. PwMOGAD performed worse on Selective Reminding Test, and the symbol digit modalities test compared to HC. Adjusted RR for CImp were 1.9 (95% CI 0.9-4.1) in pwMOGAD, 1.9 (95% CI 1.0-3.9) in pwAQP4+NMOSD and 2.1 (95% CI 0.9-4.6) in pwdsNMOSD. CONCLUSION:pwMOGAD performed worse in information processing speed, verbal learning, storage and retrieval compared to HC. RR for CImp in pwMOGAD compared to HC was similar to that estimated for pwAQP4+NMOSD and pwdsNMOSD.

    2026Journal of Neurology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1808 篇论文

    合作机构(100)

    弗里曼商学院合作论文 133
    路易斯安那州立大学合作论文 88
    昆士兰大学合作论文 58
    温纳贝戈医学中心合作论文 47
    克利夫兰诊所合作论文 45
    阿拉巴马大学伯明翰分校合作论文 43
    哥伦比亚大学合作论文 42
    华盛顿大学合作论文 33
    杜克大学合作论文 32
    埃默里大学合作论文 29

    机构统计